Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -59.97% is 36% above its 2-year average of -93.58%, around the middle of its 2-year range (-462.48%–118.51%).
0.92% below its 12-month average of -59.42%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -57.58%.
EBITDA MARGIN
-59.97%
EBITDA MARGIN AVG TTM
-59.42%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.92%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$416.68M
EBITDA Margin
-107.01%
TTM Avg
-86.79%
3Y Avg
-53.66%
5Y Avg
-431.14%
Market Cap
$410.54M
EBITDA Margin
39.39%
TTM Avg
8.38%
3Y Avg
8.38%
5Y Avg
8.38%
Market Cap
$408.21M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$406.47M
EBITDA Margin
-48.80%
TTM Avg
-44.09%
3Y Avg
-45.35%
5Y Avg
-45.35%
Market Cap
$428.16M
EBITDA Margin
-232.13%
TTM Avg
-495.69%
3Y Avg
-578.57%
5Y Avg
-532.48%
Market Cap
$447.43M
EBITDA Margin
-184.73%
TTM Avg
-138.06%
3Y Avg
-2467.18%
5Y Avg
-2497.88%
Market Cap
$450.64M
EBITDA Margin
-16.58%
TTM Avg
-87.69%
3Y Avg
-357.20%
5Y Avg
-653.36%
Market Cap
$453.70M
EBITDA Margin
-1349.20%
TTM Avg
-1349.20%
3Y Avg
-1349.20%
5Y Avg
-1349.20%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Carlsmed, Inc. (CARL) | $415.93M | -59.97% | -59.42% | N/A | N/A |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $416.68M | -107.01% | -86.79% | -53.66% | -431.14% |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $410.54M | 39.39% | 8.38% | 8.38% | 8.38% |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $408.21M | N/A | N/A | N/A | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $406.47M | -48.80% | -44.09% | -45.35% | -45.35% |
| Editas Medicine, Inc. (EDIT)vs › | $428.16M | -232.13% | -495.69% | -578.57% | -532.48% |
| Capricor Therapeutics, Inc. (CAPR)vs › | $447.43M | -184.73% | -138.06% | -2467.18% | -2497.88% |
| Assembly Biosciences, Inc. (ASMB)vs › | $450.64M | -16.58% | -87.69% | -357.20% | -653.36% |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $453.70M | -1349.20% | -1349.20% | -1349.20% | -1349.20% |
| Canopy Growth Corporation (CGC)vs › | $373.40M | -12.87% | -20.20% | -216.20% | -209.97% |
Gross Margin
76.6%
EBITDA Margin
-60.0%
Operating Margin
-61.1%
Net Margin
-57.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -57.58% |
| 2026-03-31 | -56.94% |
| 2025-12-31 | -60.80% |
| 2025-09-30 | -68.48% |
| 2025-06-30 | -53.31% |
| 2025-03-31 | -55.74% |
| 2024-12-31 | -462.48% |
| 2024-09-30 | 118.51% |
| 2024-06-30 | -103.34% |
| 2024-03-31 | -103.99% |
| 2023-12-31 | -125.28% |
